Waddill William D. sold $1.1M of PTGX
Waddill William D. sold 9,000 shares of Protagonist Therapeutics, Inc (PTGX) at $117.94 ($1.06M total) on 2026-06-23 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the director’s open-market sale of 9,000 shares at $117.94/share under a pre-arranged 10b5-1 plan; it is more relevant for sentiment/positioning than for fundamentals.
Market read
Traders may briefly reassess sentiment around PTGX, but the 10b5-1 structure limits the signal strength.
What to watch
The filing does not disclose reasons for the sale, and the transaction size is not large enough here to infer a fundamental change without corroborating company news.
Background
This is an SEC Form 4 insider transaction disclosure for Protagonist Therapeutics (PTGX).
Ticker impact
Protagonist Therapeutics director Waddill William D. sold 9,000 PTGX shares in an open-market transaction on 2026-06-23.
Low likelihood of a sustained price move solely from this Form 4 sale; any impact would be short-lived sentiment noise.
The filing is a disclosed insider sale (S) with an explicit pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
Minimal read-through to biotech sector; this is a single-insider transaction without clinical/regulatory updates.
None.
None.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can coincide with internal risk management or liquidity needs; traders may still watch for follow-on sales.
Key entities
- issuerProtagonist Therapeutics, Inc
Company whose director insider sale is disclosed on Form 4.
- insiderWaddill William D.
Director who sold 9,000 shares of PTGX on 2026-06-23 under a 10b5-1 plan.
